Suven Life Sciences Ltd (SUVEN)
₹316.00
Mkt cap
₹10,062 Cr
P/E ratio
—
P/B
14.11
Div yield
0.00%
ROE
−78.80%
ROCE
−76.90%
EPS (TTM)
—
Book value
₹22
52W range
127–360
Sector
Healthcare
Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders. [1]
Health check
Cautious
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−12.11% from high₹316
₹127+149.51% from low₹360
Current
₹316.00
Prev close
₹315.10
Day
+0.29%
Price performance
1D
+0.29%
1W
−6.65%
1M
+18.24%
3M
+56.40%
6M
+120.22%
1Y
+8.89%
YTD
+91.74%
Financials
FRevenue, profit & margin
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 4 | 3 | 2 | 2 | 1 | 3 | 2 | 1 | 2 | 1 | 3 | 2 | |
| Expenses | 34 | 32 | 27 | 49 | 33 | 32 | 55 | 41 | 45 | 53 | 81 | 106 | 52 | |
| Operating Profit | -32 | -28 | -24 | -46 | -30 | -31 | -52 | -39 | -44 | -51 | -80 | -103 | -51 | |
| OPM % | -1,208% | -737% | -768% | -1,885% | -1,267% | -3,024% | -2,032% | -2,435% | -2,981% | -2,714% | -8,671% | -3,678% | -3,331% | |
| Other Income | 6 | 6 | 13 | 6 | 4 | 4 | 4 | 2 | 1 | 1 | 4 | 3 | 7 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | |
| Profit before tax | -28 | -24 | -13 | -42 | -28 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | |
| Tax % | 0% | 0% | 0% | 0% | -4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
| Net Profit | -28 | -24 | -13 | -42 | -27 | -28 | -50 | -39 | -44 | -52 | -77 | -102 | -46 | |
| EPS in Rs | -1.27 | -1.10 | -0.58 | -1.91 | -1.22 | -1.29 | -2.28 | -1.79 | -2.01 | -2.36 | -3.40 | -4.48 | -1.73 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202670.15%Promoter
Promoters70.15%2.79
FIIs0.91%0.16
DIIs4.62%1.23
Public24.32%3.86
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Syngene Intl. | ₹420.50 | 47.11 | 16,974 | 0.30% | 148 | −11.82% | 960 | +1.22% | 9.91% |
| Indegene | ₹511.00 | 29.69 | 12,311 | 0.39% | 80 | −19.14% | 1,003 | +32.80% | 18.82% |
| Suven Life Scie. | ₹356.10 | — | 10,062 | 0.00% | −46 | −3.78% | 2 | +3.40% | −76.92% |
| Vimta Labs | ₹572.75 | 32.46 | 2,559 | 0.35% | 21 | +15.23% | 109 | +15.68% | 25.23% |
| Fabtech Tech. | ₹157.92 | 18.96 | 702 | 0.00% | 22 | +46.19% | 159 | +17.54% | 13.58% |
| Take Solutions | ₹20.74 | 72.02 | 307 | 0.00% | 4 | +1,353.33% | 54 | — | 18.51% |
| Novelix Pharma. | ₹70.01 | 77.86 | 199 | 0.00% | 1 | +405.56% | 25 | +20.76% | 9.98% |
| Median: 9 Co. | ₹157.92 | 39.78 | 702 | 0.00% | 8 | +46.19% | 109 | +16.61% | 9.98% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bseFinancial Year 2012nse
Concall transcripts35
PPTJul 2021TranscriptFeb 2020TranscriptNov 2019PPTNov 2019TranscriptAug 2019PPTAug 2019TranscriptMay 2019PPTMay 2019PPTMay 2019TranscriptFeb 2019PPTFeb 2019PPTFeb 2019PPTFeb 2019TranscriptNov 2018PPTNov 2018PPTNov 2018TranscriptAug 2018PPTAug 2018TranscriptMay 2018PPTMay 2018PPTJan 2018PPTDec 2017TranscriptNov 2017PPTNov 2017
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 1d - Special window for Re-Lodgment of transfer requests of Physical sharesAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 1dAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 10 Jul - Suven will present five posters at AAIC 2026 in London, including Masupirdine Phase-3 and Usmarapride Phase-2 updates.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 JulRevised Outcome Of The Meeting Of Board- Incorporation Of Wholly Owned Subsidiary (WOS) In Singapore 8 Jul - Board approved conversion of 1.85 crore warrants into shares for Rs 248.84 crore, reappointed director, and formed Singapore WOS.